Noninvasive imaging markers associated with XXXX .

@entity1164 @entity1 @entity32 @entity296 @entity82 @entity943 @entity737 @entity1188 @entity741 @entity204 @entity1002
UNASSIGNED: @entity1164 ( @entity1164 ) accounts for approximately 15-20% of all @entity204 worldwide. While the majority of SCDs occur in adults, @entity1 , and adults <35 years (<1%) may also be affected. Currently the most effective strategy for both primary and secondary prevention of @entity1164 is the @entity737 ( @entity737 ). However, identification of @entity1 who will benefit from @entity737 implantation remains challenging. @entity1002 ( @entity1002 ) is the most frequent imaging parameter used to select @entity1 for @entity737 implantation for primary prevention. However, @entity1002 has shown to be suboptimal for prediction of benefit. Non-invasive cardiac imaging permits characterization of the arrhythmogenic substrate, including dispersion of electromechanical activation, presence of @entity296 , and cardiac innervation status. The arrhythmogenic substrate may change across the different underlying diseases. While in @entity296 , differentiation and characterization of @entity1188 core and peri- @entity1188 zone have been shown to refine the risk stratification of @entity1 , in non-ischemic @entity296 , the substrate may be more heterogeneous and tissue characterization assessing focal and diffuse @entity82 and @entity32 processes may be more relevant. Furthermore, in channelopathies, assessment of mechanical dispersion between @entity296 may identify the @entity1 with increased risk of @entity943 . Finally, potential triggers of @entity943 such as @entity741 can be evaluated. The role of noninvasive imaging in the risk stratification of @entity1164 and the selection of candidates for @entity737 will be discussed in this article.
